The challenge for development of valuable immuno-oncology biomarkers

Janice M. Mehnert, Arta M Monjazeb, Johanna M.T. Beerthuijzen, Deborah Collyar, Larry Rubinstein, Lyndsay N. Harris

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must be developed to identify which patients are likely to achieve benefit. To minimize therapeutic toxicities and costs, understanding the ideal choice and sequencing of the numerous immuno-oncology agents available for individual patients is thus critical, but fraught with challenges. The immune tumor microenvironment (TME) is a unique aspect of the response to immuno-oncology agents and measurement of single biomarkers does not adequately capture these complex interactions. Therefore, multiple potential biomarkers are likely needed. Current candidates in this area include PD-L1 expression, CD8+ tumor-infiltrating lymphocytes, tumor mutation load and neoantigen burden, immune-related gene signatures, and multiplex IHC assays that examine the pharmacodynamic and spatial interactions of the TME. The most fruitful investigations are likely to use several techniques to predict response and interrogate mechanisms of resistance. Immuno-oncology biomarker research must employ validated assays to ask focused research questions utilizing clinically annotated tissue collections and biomarkerfocused clinical trial designs to investigate specific endpoints. Real-time input from patients and their advocates into biomarker discovery is necessary to ensure that the investigations pursued will improve both clinical outcomes and quality of life. We herein provide a framework of recommendations to guide the search for immuno-oncology biomarkers of value.

Original languageEnglish (US)
Pages (from-to)4970-4979
Number of pages10
JournalClinical Cancer Research
Volume23
Issue number17
DOIs
StatePublished - Sep 1 2017

Fingerprint

Biomarkers
Tumor Microenvironment
Immunotherapy
Tumor-Infiltrating Lymphocytes
Tumor Burden
Research
Neoplasms
Quality of Life
Clinical Trials
Costs and Cost Analysis
Mutation
Therapeutics
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D., Rubinstein, L., & Harris, L. N. (2017). The challenge for development of valuable immuno-oncology biomarkers. Clinical Cancer Research, 23(17), 4970-4979. https://doi.org/10.1158/1078-0432.CCR-16-3063

The challenge for development of valuable immuno-oncology biomarkers. / Mehnert, Janice M.; Monjazeb, Arta M; Beerthuijzen, Johanna M.T.; Collyar, Deborah; Rubinstein, Larry; Harris, Lyndsay N.

In: Clinical Cancer Research, Vol. 23, No. 17, 01.09.2017, p. 4970-4979.

Research output: Contribution to journalArticle

Mehnert, JM, Monjazeb, AM, Beerthuijzen, JMT, Collyar, D, Rubinstein, L & Harris, LN 2017, 'The challenge for development of valuable immuno-oncology biomarkers', Clinical Cancer Research, vol. 23, no. 17, pp. 4970-4979. https://doi.org/10.1158/1078-0432.CCR-16-3063
Mehnert, Janice M. ; Monjazeb, Arta M ; Beerthuijzen, Johanna M.T. ; Collyar, Deborah ; Rubinstein, Larry ; Harris, Lyndsay N. / The challenge for development of valuable immuno-oncology biomarkers. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 17. pp. 4970-4979.
@article{8f1702ca5fe3496ebabe70246559b932,
title = "The challenge for development of valuable immuno-oncology biomarkers",
abstract = "The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must be developed to identify which patients are likely to achieve benefit. To minimize therapeutic toxicities and costs, understanding the ideal choice and sequencing of the numerous immuno-oncology agents available for individual patients is thus critical, but fraught with challenges. The immune tumor microenvironment (TME) is a unique aspect of the response to immuno-oncology agents and measurement of single biomarkers does not adequately capture these complex interactions. Therefore, multiple potential biomarkers are likely needed. Current candidates in this area include PD-L1 expression, CD8+ tumor-infiltrating lymphocytes, tumor mutation load and neoantigen burden, immune-related gene signatures, and multiplex IHC assays that examine the pharmacodynamic and spatial interactions of the TME. The most fruitful investigations are likely to use several techniques to predict response and interrogate mechanisms of resistance. Immuno-oncology biomarker research must employ validated assays to ask focused research questions utilizing clinically annotated tissue collections and biomarkerfocused clinical trial designs to investigate specific endpoints. Real-time input from patients and their advocates into biomarker discovery is necessary to ensure that the investigations pursued will improve both clinical outcomes and quality of life. We herein provide a framework of recommendations to guide the search for immuno-oncology biomarkers of value.",
author = "Mehnert, {Janice M.} and Monjazeb, {Arta M} and Beerthuijzen, {Johanna M.T.} and Deborah Collyar and Larry Rubinstein and Harris, {Lyndsay N.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-16-3063",
language = "English (US)",
volume = "23",
pages = "4970--4979",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - The challenge for development of valuable immuno-oncology biomarkers

AU - Mehnert, Janice M.

AU - Monjazeb, Arta M

AU - Beerthuijzen, Johanna M.T.

AU - Collyar, Deborah

AU - Rubinstein, Larry

AU - Harris, Lyndsay N.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must be developed to identify which patients are likely to achieve benefit. To minimize therapeutic toxicities and costs, understanding the ideal choice and sequencing of the numerous immuno-oncology agents available for individual patients is thus critical, but fraught with challenges. The immune tumor microenvironment (TME) is a unique aspect of the response to immuno-oncology agents and measurement of single biomarkers does not adequately capture these complex interactions. Therefore, multiple potential biomarkers are likely needed. Current candidates in this area include PD-L1 expression, CD8+ tumor-infiltrating lymphocytes, tumor mutation load and neoantigen burden, immune-related gene signatures, and multiplex IHC assays that examine the pharmacodynamic and spatial interactions of the TME. The most fruitful investigations are likely to use several techniques to predict response and interrogate mechanisms of resistance. Immuno-oncology biomarker research must employ validated assays to ask focused research questions utilizing clinically annotated tissue collections and biomarkerfocused clinical trial designs to investigate specific endpoints. Real-time input from patients and their advocates into biomarker discovery is necessary to ensure that the investigations pursued will improve both clinical outcomes and quality of life. We herein provide a framework of recommendations to guide the search for immuno-oncology biomarkers of value.

AB - The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must be developed to identify which patients are likely to achieve benefit. To minimize therapeutic toxicities and costs, understanding the ideal choice and sequencing of the numerous immuno-oncology agents available for individual patients is thus critical, but fraught with challenges. The immune tumor microenvironment (TME) is a unique aspect of the response to immuno-oncology agents and measurement of single biomarkers does not adequately capture these complex interactions. Therefore, multiple potential biomarkers are likely needed. Current candidates in this area include PD-L1 expression, CD8+ tumor-infiltrating lymphocytes, tumor mutation load and neoantigen burden, immune-related gene signatures, and multiplex IHC assays that examine the pharmacodynamic and spatial interactions of the TME. The most fruitful investigations are likely to use several techniques to predict response and interrogate mechanisms of resistance. Immuno-oncology biomarker research must employ validated assays to ask focused research questions utilizing clinically annotated tissue collections and biomarkerfocused clinical trial designs to investigate specific endpoints. Real-time input from patients and their advocates into biomarker discovery is necessary to ensure that the investigations pursued will improve both clinical outcomes and quality of life. We herein provide a framework of recommendations to guide the search for immuno-oncology biomarkers of value.

UR - http://www.scopus.com/inward/record.url?scp=85029508221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029508221&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-3063

DO - 10.1158/1078-0432.CCR-16-3063

M3 - Article

C2 - 28864725

AN - SCOPUS:85029508221

VL - 23

SP - 4970

EP - 4979

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -